Biodesix® Announces Additional Data in Phase III Lung Cancer Diagnostic Study
PROSE confirms VeriStrat can predict differential treatment outcomes in 2nd line advanced NCLSC patients.
×
254 Results
PROSE confirms VeriStrat can predict differential treatment outcomes in 2nd line advanced NCLSC patients.
Randomised Proteomic Stratified Phase III Study of Second Line Erlotinib Versus Chemotherapy in Patients with Inoperable Non-Small Cell Lung Cancer (PROSE)
Data confirms that the blood-based protein diagnostic is predictive of differential treatment outcomes between two types of therapies for 2nd line NSCLC.
Biodesix announced the issuance of three additional patents. Two which provide intellectual property protection and the other for Veristrat.
Dr. Roder will discuss the use of Biodesix’ high throughput mass spectrometry technology, Deep MALDI, to generate protein signatures for Oncology questions.
VeriStrat test was able to identify patients likely to have better and worse survival outcomes when treated with the combination therapy.
The intention of the biomarker analysis was to evaluate the ability of VeriStrat, to predict patient outcomes with a combination regimen.
Paul Beresford, Ph.D., will present at the 2013 World CDx Summit taking place in Boston, November 12-15, 2013; Benefits of proteomics in test discovery.
Biodesix and Progenetics have entered into an international agreement; Biodesix tests will be available in Israel for the first time.
Biodesix Inc. announced today that the company has raised $7.1 million in new equity financing, led by existing investors.